RSV Seasonal Vaccine Introduction and Growth Strategy
Effective capital allocation to support R&D investment priorities
Invest for growth
Pipeline
New product launches
Infectious
Diseases
Organic R&D portfolio and targeted Business Development
Criteria: First-in-class or best-in-class, probability of success, commercial potential, and risk/return, technology enabled
HIV
Respiratory/
Immunology
Oncology
Pioneering novel platform technologies to
help prevent and treat seasonal respiratory
viruses, bacterial, fungal and chronic viral
infections
Novel treatment and prevention options to
significantly improve the patient experience
Slow disease progression, address
treatment resistance and reduce signs and
symptoms of disease
Seeking solutions for blood and women's
cancers and break-throughs in immuno-
oncology
GSK
10View entire presentation